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Abstract
Background: Integration of human immunodeficiency virus type 1 (HIV-1) into a host cell chromosome is an
essential step under the control of the viral integrase (IN). Although this enzyme is necessary and sufficient to
catalyze the integration reaction in vitro, cellular cofactors are involved in the process in vivo. The chromatin-
associated factor LEDGF/p75 interacts with IN and promotes integration to transcription units of the host genome.
HIV-1 IN also binds the karyopherin TNPO3, however the significance of this interaction during viral replication
remains to be explored.
Results: Here we present a functional analysis of IN mutants impaired for LEDGF/p75 and TNPO3 interaction.
Among them, IN W131A and IN Q168L, that were previously identified to be deficient for LEDGF/p75 interaction,
were also partially impaired for TNPO3 binding. We observed that mutations abolishing IN ability to form tetramers
resulted in a severe reduction in LEDGF/p75 binding. In sharp contrast, no correlation could be found between the
ability of IN to multimerize and TNPO3 interaction. Most of the mutant viruses were essentially impaired for the
integration step whereas the amount of 2-LTR circles, reflecting the nuclear import of the viral DNA, was not
significantly affected.
Conclusion: Our functional analysis of HIV-1 IN mutants reveals distinct structural basis for TNPO3 interaction and
suggests that the interaction between IN and TNPO3 is not a major determinant of nuclear import but could take
place at a nuclear step prior to integration.
Background
Following the entry of the HIV-1 viral core into the
cytoplasm of a target cell, reverse transcription of the
retroviral RNA into a linear double strand cDNA copy
takes place within the reverse transcription complex
(RTC) [1,2]. Once synthesized by the RTC, this viral
cDNA becomes part of a large nucleoprotein complex
called the pre-integration complex (PIC) [3-5]. HIV-1
PICs retain components of the RTC: nucleocapsid (NC),
integrase (IN), matrix (MA), Vpr and reverse transcrip-
tase (RT) [3,6], together with cellular cofactors. This
complex is transported to the nucleus where the viral
cDNA integrates into a host cell chromosome, a key
step that is under the control of the retroviral enzyme
IN [7-9]. Whereas the recombinant HIV-1 IN protein is
sufficient to catalyze the 3’ processing and strand trans-
fer activities for in vitro integration, functional interac-
tions between IN and host cell factors are required
during the early events of HIV-1 replication in vivo
[10-12].
HIV-1 host cell factor dependency is well illustrated
by LEDGF/p75, a cellular chromatin-associated protein
involved in transcriptional regulation of cellular genes
that were identified as an IN interacting factor
[11,13,14]. LEDGF/p75 plays an important role in lenti-
viral cDNA integration, as demonstrated by mutagenesis
[14-17], over-expression of LEDGF/p75 IBD (Integrase
Binding Domain) [18,19], as well as RNAi and knock-
out studies [18-23]. Structural studies revealed the roles
of both the catalytic core domain (CCD) dimeric
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interface as well as the N-terminal domain (NTD) of IN
for high affinity binding to IBD [16,24,25]. In addition,
LEDGF/p75 stimulates the formation of IN tetramers,
which are required for efficient concerted integration of
both viral ends into host DNA [26-29]. Furthermore,
the targeting of viral integration to specific regions of
the host chromosome is under the control of LEDGF/
p75. Indeed, LEDGF/p75 guides the site selection of len-
tiviral integration within transcription units (TUs) of
transcriptionally active genes, while GpC islands and
promoter regions are disfavored [20,21,30]. Albeit not
strictly essential for replication, LEDGF/p75 tethers
PIC-associated IN to chromatin to presumably stimulate
its enzymatic activity at the site of integration [31,32].
In contrast to the gammaretrovirus Moloney murine
Leukemia Virus (MLV), HIV-1 and other lentiviruses
possess the ability to infect both dividing and non-divid-
ing cells [33,34]. This specificity is particularly important
to explain the infection of terminally differentiated cells,
including macrophages and microglia that constitute an
important reservoir of virus in infected individuals [35].
In these cells, the mechanisms leading to the establish-
ment of an integrated provirus are still unclear. One key
step could be the nuclear import of the PIC, which
must be translocated through the intact nuclear mem-
brane in an energy dependent manner. To pass through
the nuclear pore complex (NPC), components of the
PIC must interact with cellular nucleo-cytoplasmic
transport factors as well as NPC components such as
nucleoporins (NUPs). Several viral determinants, includ-
ing karyophilic signals of MA, Vpr or IN, as well as the
viral flap DNA structure could contribute to the nuclear
import of the PIC; however, their exact role is still
debated (see [36-38] for recent reviews). In contrast, CA
recently emerged to be a key factor in conferring the
ability of HIV-1 to infect non-dividing cells. While evi-
dence of a direct interaction between CA and the
nuclear import machinery is still lacking, CA uncoating
of the core appears to be coupled with an active nuclear
translocation [39-41]. CA dissociation could allow sub-
sequent interactions of viral karyophilic motifs with
nuclear import factors. Alternatively, it was observed
that intact capsid lattices remain associated with the
PIC and that uncoating of the core occurs at the nuclear
pore upon completion of the reverse transcription [42].
The cellular factors involved in PIC nuclear import
have been the focus of numerous and often contradic-
tory studies. Members of the importin a protein family
were previously shown to interact with IN [43-50].
Importin 7, a nucleocytoplasmic factor related to impor-
tin b, was also implicated in this process by directly
interacting with IN [48,51,52]. In addition to karyopher-
ins, several components of the nuclear pore complex
(NPC) were identified to play a role in early steps of
HIV-1 replication [53-57].
Using genome-wide RNAi knock down approaches,
TNPO3 was recently identified as a HIV-dependency
factor involved at a stage between reverse transcription
and integration [53,55]. TNPO3 belongs to the importin
b family that plays the role of transporter of serine/argi-
nine rich (SR) proteins into the nucleus [58-61]. TNPO3
was shown to mediate nuclear import of the PIC, both
in dividing and non-dividing cells [62]. We identified
TNPO3 as a partner of IN by yeast two-hybrid (y2H)
screenings using IN as a bait, and rebound screenings
using an HIV-1 library confirmed that TNPO3 interacts
solely with IN [62,63]. Whereas a direct interaction
between HIV-1 IN and TNPO3 was confirmed by differ-
ent studies [62-64], its relevance in HIV-1 replication
has been questioned. For instance, no correlation could
be found between the affinity of TNPO3 for different
retroviral INs and its requirement during infection
[64,65]. Instead, studies pinpointed to a dominant role
of CA for TNPO3 dependency [64,66].
Here, we assessed the role of TNPO3-IN interaction
in HIV-1 replication. Site-directed mutagenized IN pro-
teins were analyzed for LEDGF/p75 and TNPO3 inter-
action. The structure function analysis of these mutants
revealed that mutations previously characterized to
impair LEDGF/p75 binding also affected interaction
with TNPO3. However, contrary to what was observed
for LEDGF/p75, TNPO3 binds IN regardless to its tetra-
meric state. Importantly, while impairing HIV-1 replica-
tion, none of these mutations significantly affected
amounts of 2-LTR circles, indicating a lack of correla-
tion between the ability of IN to interact with TNPO3
and nuclear import of HIV-1.
Results
Recent retroviral intasome structures revealed a tetra-
mer of IN formed by a dimer-of-dimers [28,67]. To
characterize whether the tetramerization of HIV-1 IN
was involved in TNPO3 interaction, we analyzed
mutants of IN that are affected in their abilities to mul-
timerize. Residues Lys188 and Tyr194 within the CCD
of IN are located within a loop connecting CCD helices
a5 and a6 involved in tetramerization [26] (Figure 1A).
Lys188 forms a salt bridge with Asp25 at the intermole-
cular NTD-CCD interface, while Tyr194 is involved in
the hydrophobic interaction at the dimer-dimer interface
[26,27] (Figure 1B). Alongside these residues, we also
included in our assays two previously characterized IN
mutants W131A and Q168L that were deficient for
LEDGF/p75 binding [14,15,17]. The residue Q168 does
not interact directly with LEDGF/p75, but hydrogen-
bond with W132 from the opposite IN monomer,
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therefore participating in the dimerization of IN (Figure
1C). The residue W131 is directly involved in hydropho-
bic contacts with LEDGF/p75 residues F406 and V408
[16,24-26].
Purified HIV-1 IN exists in solution as a mixture of
multiple oligomerized forms containing monomers,
dimers and tetramers, even in absence of DNA. We
used size exclusion chromatography (SEC) to assess the
multiple multimeric states of our tag-free IN mutants.
In this assay, wild type IN was predominantly tetra-
meric, with the presence of two smaller peaks corre-
sponding to the dimeric and monomeric forms. IN
W131A behaved mostly as a mixture of tetramers and
dimers. In sharp contrast, mutation Q168L disrupting
the Q168-W132 H-bond results in a major shift to a
low molecular weight peak corresponding exclusively to
monomers. Substitution of the Lys188 residue to a Gln,
targeting the Asp25:Lys188 intra-molecular salt bridge,
also led to a monomeric form of IN. A recent crystal
structure of IN tetramers pinpointed a role of residue
Tyr194 in the closure of the dimer-dimer interface [26].
Substitution of Tyr194 by hydrophobic residue Phe
resulted in an elution profile similar to wild type IN.
Remarkably, mutation Y194E led to a pronounced shift
to monomeric forms. These results are in good agree-
ment with previous reports highlighting a role of the
186-195 loop in the tetramerization of IN [26,27] (Fig-
ure 2).
HIV-1 IN concerted integration activities are closely
linked to its multimerization state [68-70]; thus, we next
analyzed the effects of these mutations on the reactions
catalyzed in vitro by the retroviral enzyme. We first
assessed the effect of these mutations on intrinsic 3’
processing and strand transfer activities. The W131A,
Q168L, K188Q and Y194F IN mutants retained near
wild type 3’ processing activity, while the Y194E mutant
was impaired (Figure 3A lower panel and 3B lower
panel). The W131A mutant also displayed wild type
level of strand transfer activity. The mutations Q168L,
K188Q and Y194F partially decreased strand transfer
activity. Again, mutant Y194E was more severely
affected (Figure 3A upper panel and 3B upper panel).
We next assessed the ability of these mutants to per-
form in vitro concerted integration under previously
reported conditions [68]. Using a 296 bp DNA substrate
containing the 21 nt of both pre-processed HIV-1 U3
and U5 viral ends at each extremity, IN WT displayed a
robust activity generating all the expected integration
products including the half site integration product
(HSI) and the full site integration product (FSI). IN
W131A displayed a strong activity at 5 pmoles. Surpris-
ingly, despite its monomeric elution profile in SEC (Fig-
ure 2), Q168L retained a significant catalytic activity. In
sharp contrast, K188Q, Y194F and Y194E were almost
incapable of concerted integration activities (Figure 3C).
In order to assess the impact of IN multimerization on
LEDGF/p75 and TNPO3 binding, we first confirmed
that our recombinant proteins were able to interact in a
Ni-NTA pull-down assay. As expected, His-tagged wild
type IN interacted with both full length GST-LEDGF/
p75 and GST-TNPO3, while the GST protein alone
failed to be pulled down. IN also recovered the IBD of
LEDGF/p75 that was previously identified in yeast 2-
hybrid screenings [14] (Additional file 1: Figure S1). In
the absence of His-IN, none of the GST fusion proteins
were recovered (data not shown). Next, we established a
more quantitative assay to assess the binding properties
of our mutants. In vitro interactions were studied by
HTRF, a FRET-based assay using His-IN and either
LEDGF/P75 or TNPO3 constructs tagged with GST.
Recombinant proteins were incubated to form a com-
plex in presence of anti-GST-EuCryptate/anti-His-
XL665, and the transfer of energy between the two pro-
teins yields a fluorescent signal only if they are in close
proximity, i.e. if they are physically interacting. IN
mutants were first characterized for their ability to bind
LEDGF/p75. The His-IN::GST-LEDGF/p75 complex
yielded a strong and reproducible signal reflecting the
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Figure 1 HIV-1 integrase mutants. (A) Crystal structure of an INNTD-CCD tetramer ABCD (PDB ID 1k6y, [89]) represented in ribbons. Individual
subunits of IN are colored blue, cyan, red, and gold. (B) At the NTD-CCD interface, the ε-amine of Lys188 is located at 2.8 Å from Asp25 making
and H-bond and at 4.5 Å from Glu198 (also indicated). (C) INCCD LEDGF/p75IBD interface (PDB ID 2b4j, [24]). Individual subunits of IN are colored
in blue and cyan, LEDGF/p75IBD is colored in grey.
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robustness of this assay. As previously reported, both IN
W131A and IN Q168L displayed a weak interaction
with LEDGF/p75 (9.3 and 16.3% of IN WT interaction
in our assay, respectively). Substitution of Lys188 for a
Gln also resulted to a 64.9% decrease of the binding to
LEDGF/p75. While IN Y194F interacted with LEDGF/
p75 at wild type level, the substitution of Tyr for a nega-
tively charged Glu or a neutral Ala moderately dimin-
ished IN binding to LEDGF/p75 by 26 and 27%
respectively (Figure 4A).
The same assay was developed to quantify IN::TNPO3
interaction. Both IN mutants K188Q and Y194A inter-
acted with TNPO3 as well as IN WT, while the substi-
tution of Y194 to Phe or Glu resulted in a 14.4 and
23.5% decrease of TNPO3 binding. Surprisingly, the
strongest decrease for TNPO3 binding was observed for
both LEDGF/p75 interaction-defective integrase IN
W131A and IN Q168L (49% and 45% of IN WT,
respectively) (Figure 4B).
In order to determine the impact of these mutations
on the viral replication in infected cells, they were intro-
duced into the replicative Bru molecular clone; and viral
stocks were produced. Among the IN mutants virus,
only HIV-1 W131A displayed a severe reduction of viral
particle release, yielding 16% of wild-type Cap24 release
(Figure 5A). To assess the ability of IN mutant viruses
to replicate, SupT1 cells were infected with equal
amount of WT or mutant viruses, and viral replication
was monitored by measuring p24 antigen in the super-
natant of infected cells. Compared to the wild-type
virus, HIV-1 W131A showed a 7 days delay in break-
through whereas HIV-1 Q168L, HIV-1 K188Q, and
HIV-1 Y194E and HIV-1 Y194F mutants were replica-
tion-deficient (Figure 5B).
We analyzed the impact of IN mutations on early
stages of HIV-1 replication using real-time quantitative
PCR. Preliminary observations in HeLa cells indicated
that some of our IN mutant viruses displayed strong
cDNA synthesis defects when pseudotyped with the
vesicular stomatitis virus glycoprotein (VSVg) (Addi-
tional file 2: Figure S2). Interestingly, these defects could
be compensated when viruses entered cells by fusion
using HIV-1 gp120 envelope suggesting that IN muta-
tions could affect pre-integration steps specific to the
VSVg-mediated endocytic pathway (Figure 6A and
Additional file 2: Figure S2). Thus, utilizing real-time
quantitative PCR, we first measured late reverse tran-
scribed (LRT) viral cDNA products, 2-LTR circles and
integrated proviral DNA in SupT1 cells infected with IN
mutant viruses encoding HIV-1 env. In this experiment,
virus replication was restricted to a single round infec-
tion by addition of Saquinavir, a protease inhibitor. At 7
h post infection, HIV-1 WT, HIV-1 Q168L, HIV-1
K188Q, HIV-1 Y194E and HIV-1 Y194F viruses synthe-
sized similar amount of LRT viral cDNA products,
whereas HIV-1 W131A displayed a 2.7-fold defect (Fig-
ure 6A). Detection of 2-LTR circle forms of viral HIV-1
cDNA is indicative of nuclear import of the viral gen-
ome. At 24h p.i., HIV-1 Q168L, HIV-1 K188Q, HIV-1
Y194E and HIV-1 Y194F mutant viruses converted
equal or slightly higher amounts of 2-LTR circles (1.3-
fold, 1.0-fold, 1,2-fold and 1.6-fold, respectively) com-
pared to the wild type virus whereas HIV-1 W131A
yielded an approximate 4-fold reduction (Figure 6B).
Figure 2 Oligomerization properties of WT and mutant INs. Size exclusion chromatography (SEC) elution profiles of IN proteins (2.5 μM)
versus elution volumes of protein standards (black arrows) are represented. The SEC profile of WT IN (dark blue) shows three peaks
corresponding to tetramers, dimers and monomers, respectively. SEC profiles of IN mutants W131A, Q168L, K188Q, Y194E and Y194F are shown
in red, green, orange, cyan and purple, respectively.
Cribier et al. Retrovirology 2011, 8:104
http://www.retrovirology.com/content/8/1/104
Page 4 of 14
W1
31
A
WT Q1
68
L
Y1
94
F
Y1
94
E
K1
88
Q
mo
ck
3’ p
21mer
19mer
strand
transfer
products
1 2 3 4 5 6 7 8 9 10111213
A
C
d/d
FSI
HSI+FSI
W1
31
A
WT Q1
68
L
Y1
94
F
Y1
94
E
K1
88
Q
1 2 3 4 5 6 7 8 9 10 11 12
HSI FSI
FSI (linear)
Target
donor
HSI+FSI (circular)
donor/donor
+
+ integrase
+
+
1 2 3 4 5 6 7 8 9 10 11 12 13
0
5
10
15
20
25
30
1 2 3 4 5 6 7 8 9 10 11 12 13
0
4
8
12
16
20
re
la
tiv
e 
ac
tiv
ity
re
la
tiv
e 
ac
tiv
ity
3’ processing
strand transfer
B
Figure 3 Enzymatic activities of WT and mutant INs. (A) 3’ processing and strand transfer activities of IN mutants. Using an oligonucleotide-
based assay, activities of recombinant INs were tested at two different concentrations: 100 nM (lanes 2, 4, 8, 10, 12); or 120 nM (lanes 3, 5, 7, 9,
11, 13). Reaction products were separated in a denaturing urea gel and visualized with a STORM PhosphorImager (Molecular Dynamics). (B)
Quantification of 3’-processing and strand transfer activities of IN mutants. Gels from figure 3A were quantified with Image Quant™ 4.1 software.
(C) Concerted integration assay was performed using IN (2 pmoles, lanes 1, 3, 5, 7, 9, 11 and 5 pmoles, lanes 2, 4, 6, 8, 10, 12), 150 ng of naked
acceptor DNA (3000 bp) and 15 ng of 32P 5’-labelled donor pre-processed DNA (296 bp). The reaction products were loaded on 1% agarose.
The positions of the different products obtained after half-site integration (HSI), full-site integration (FSI) and donor/donor integration (d/d)
are reported.
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When normalized to the quantity of LRT viral cDNA
products , HIV-1 W131A displayed about 63% of the
wild-type 2-LTR circles level, whereas HIV-1 Q168L,
HIV-1 K188Q, HIV-1 Y194E and HIV-1 Y194F dis-
played about 145%, 90%, 140% and 146% of the HIV-1
WT, respectively (Figure 6C). Finally, levels of integrated
proviruses at 48 h p.i. were severely reduced for all the
mutants (12 to 24% of that of the wild type), indicating
that these mutations primarily impact the integration
step (Figure 6D).
IN mutations affecting both nuclear import and integra-
tion could result in opposite effects on the accumulation
of 2-LTR circles in the nucleus. Because IN mutants
W131A and Q168L are impaired for interaction with
both TNPO3 and LEDGF/p75, we decided to assess
more precisely the impact of these mutations on nuclear
import in the absence of LEDGF/p75. Using LEDGF/
p75-depleted SupT1 cells [71], we quantified 2-LTR cir-
cles levels upon infection with our mutant viruses. LRT
viral cDNA products and 2-LTR circles were quantified
at 7 h and 24 h p.i., respectively. For this experiment,
LRT viral cDNA products were quantified using primers
and a Taqman probe within the env region [72]. When
compared to the WT virus, HIV-1 W131A and HIV-1
Q168L displayed about 50.7% and 36.9% decrease in
LRT viral cDNA products, respectively. In contrast,
HIV-1 K188Q synthesized amounts of reverse tran-
scribed viral cDNA products similar to wild type level
(111.6%) (Figure 7A). At 24 h p.i., HIV-1 W131A and
HIV-1 Q168L displayed 31.3% and 72.4% of wild type
levels of 2-LTR circles, respectively, whereas HIV-1
K188Q displayed a 1.6-fold increase (Figure 7B). When
normalized to the quantity of LRT viral cDNA products,
HIV-1 W131A, HIV-1 Q168L and HIV-1 K188Q con-
verted 65.5%, 114.9% and 146.0% of their LRT viral
cDNA products in to 2-LTR circles, respectively (Figure
7C). Together, these data suggest that IN mutations
reducing TNPO3 binding have a rather limited effect
(W131A) or no effect (Q168L) on nuclear import of the
PIC.
Discussion
Site-direct mutagenesis experiments previously identified
LEDGF/p75-binding deficient IN mutants [14,15,17].
Among the residues analyzed in this study, W131 is the
only one that makes a direct contact with LEDGF/p75
IBD. W131 forms hydrophobic contacts with LEDGF/
p75 residues F406 and V408. The side chain of the sur-
face exposed W131 residue was shown to rotate upon
LEDGF/p75 binding [24], and mutation of this residue
significantly impaired LEDGF/p75 interaction [17,73].
The elution profile of W131A resembled the one of IN
WT consisting of a mixture of mono-, di- and tetramers
with a predominance of dimeric forms (Figure 2). Con-
sistent with this observation, IN W131A reached near
WT concerted integration activity at its highest concen-
tration (Figure 3B).
Our structure-function analysis of IN mutants identi-
fied residues important for the oligomerization of IN.
Mutations Q168L, K188Q and Y194E that destabilized
IN multimers also affected LEDGF/p75 binding in our
HTRF assay. Whereas the Q168 residue is not directly
binding LEDGF/p75 IBD, it forms a hydrogen bound
with W132 that is important for the IN dimer interface
Figure 4 In vitro interaction assay of IN mutants with LEDGF/
p75 and TNPO3. Interaction between INs and LEDGF/p75 (A) or
TNPO3 (B) was measured by HTRF. GST-LEDGF/p75 (5 nM) or GST-
TNPO3 (5 nM) and His-IN WT or indicated IN mutants (80 nM) were
incubated with anti-GST-Europium Cryptate and anti-His-XL
antibodies. HTRF signal was read at 2 h post incubation in a
Pherastar (BMG) at 665 and 620 nm after excitation at 337 nm. HTRF
signals of indicated IN mutants were expressed as a percent IN WT
ΔF. Results are an average of three (IN::LEDGF/p75) or four (IN::
TNPO3) experiments performed in duplicate. Statistical significance
values were calculated using a student two-sided t test. ***, P <
0.0001; **, P < 0.001; *, P < 0.01.
Cribier et al. Retrovirology 2011, 8:104
http://www.retrovirology.com/content/8/1/104
Page 6 of 14
and mutations altering Q168 impaired LEDGF/p75
binding (Figure 4A). The Q168L mutant behaved solely
as a monomer, confirming that alteration of the confor-
mation of the CCD a4/a5 connector reduces IN affinity
for LEDGF/p75 (Figure 4A). The result of this confor-
mational alteration provides an explanation for the repli-
cation defect previously described for HIV-1 Q168L
([14,17,73] and Figure 5B). The residues K188 and Y194
are within the constrained loop contributing to the IN
tetrameric interface [26,27]. Consistent with previous
results, we found that IN K188Q mutant was predomi-
nantly monomeric (Figure 2) and showed almost 3-fold
decrease for LEDGF/p75 interaction (Figure 4A). Muta-
tion Y194E was also compromised for tetramer forma-
tion, although to a lesser extent, as tetramers forms
were still present. Accordingly, this mutation resulted in
a 25% decreased affinity for LEDGF/p75. In sharp con-
trast, Y194F displayed WT SEC profile and retained
high affinity for LEDGF/p75.
On the other hand, this mutagenesis study could not
establish a correlation between the formation of IN tet-
ramers and TNPO3 binding. Indeed, W131A and
Q168L displayed the strongest decreases in TNPO3
binding while showing opposite oligomerization profiles.
Figure 5 Analysis of viral production and replication. (A) 293T cells were transfected with the WT or mutant pBru molecular clones. Viral
release was monitored by quantification of CAp24 antigen in the supernatant of the producer cells 48 h after transfection. Results are
represented as a percentage of WT CAp24 release. Error bars represent standard deviations of duplicate transfections. (B) SupT1 cells were
infected with equal amounts of viruses. Viral replication was followed at indicated d.p.i. by measuring CAp24 antigen in the supernatant of
infected cells.
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Furthermore, the ability of monomeric IN to interact
with TNPO3 was further confirmed with the mutant
K188Q. These results suggest that TNPO3 could bind
to a surface of monomeric IN that remains exposed
after tetramerization. Despite its SEC monomeric pro-
file, the Q168L mutant retains some catalytic activity in
vitro. However this mutation must alter the overall con-
formation of the protein and its ability to interact with
cellular cofactors. On the contrary, the W131A mutant
displayed in vitro catalytic activities as well as multimer-
ization profile similar to the wild type IN, indicating
that this mutation has limited impact on the conforma-
tion of the protein. Results from our HTRF assay con-
firmed previous studies showing that both IN W131A
and IN W131D were defective for LEDGF/p75 binding
in His-IN pull down assays [15,17].
We observed that the oligomerization profiles of IN
mutants in solution could not completely predict their
Figure 6 IN mutants are primarily impaired at the integration step. SupT1 cells were infected in a single round experiment with equal
amounts of WT or mutants Bru viruses. At 7 h, 24 h and 48 h post infection (p.i.), cellular DNA was extracted and quantified for (A) late reverse
transcribed (LRT) viral cDNA products at 7 h p.i., (B) 2-LTR circles at 24 h p.i., and (D) integrated proviral DNA at 48 h p.i., using a real time
quantitative PCR. Results are expressed as the percentage of WT products. Depending on the mutant, error bars represent standard deviations of
n = 2 to n = 6 experiments performed in duplicate. (C) 2-LTR circles were normalized to LRT viral cDNA products.
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capacities to perform concerted strand transfer reaction.
This is exemplified by the ability of the mutant Q168L
to retain partial concerted integration activity (Figure
3B), suggesting that the monomeric IN Q168L could oli-
gomerize in presence of DNA. We also observed that
mutations of the residue Y194 strongly affected the
enzymatic activity of the protein independently of their
abilities to tetramerize probably by affecting directly the
catalytic property of the protein (Figure 3A).
Our interaction assays indicate that IN mutants
W131A and Q168L are the most deficient for TNPO3
interaction. The primarily replication defect of HIV-1
W131A takes place during reverse transcription indicat-
ing that this mutation somehow impacts the RTC con-
formation. Subsequently, the slight reduction in 2-LTR
circles could be an indirect consequence of the reverse
transcription defect. On the other hand, the HIV-1
Q168L virus displayed modest increase of 2-LTR circles
level and viral replication appears to be mainly impaired
at the integration step (Figures 6 and 7). Mutations of
IN affecting simultaneously nuclear import and integra-
tion would have opposite effects on the accumulation of
2-LTR circles in the nucleus, resulting in a null effect.
To uncoupled the phenotype of these mutant viruses on
nuclear entry from the phenotype due to the defective
interaction between IN and LEDGF/p75, we quantified
2-LTR circle levels in LEDGF/p75-depleted cells [71].
Similar to the results obtained in SupT1 cells, we
observed a 30% decrease in the formation of 2-LTR cir-
cles for HIV-1 W131A, whereas HIV-1 Q168L accumu-
lated near wild type amounts (Figure 7C). Therefore, the
study of these two IN mutants showed that no direct
correlation could be found between a defect in TNPO3
binding and the formation of 2-LTR circles. Taken
together, these results suggest that the interaction
between IN and TNPO3 is not directly involved at the
nuclear import step, but could rather take place at a
later stage in the nucleus. As quantification of 2-LTR
circles is only an indirect measurement of nuclear
import, these results should be confirmed using more
direct methods [74,75]. Nevertheless, these results cor-
roborate mounting evidence against a direct role of IN
in controlling the shuttling of the PIC between the cyto-
plasm and the nucleus in dividing or non-dividing cells
[76,77].
Furthermore, CA was found to be the dominant viral
determinant for HIV-1 infection of non-dividing cells.
The kinetic of dissociation of CA from the viral core
appears to be a critical step that could control subse-
quent interactions with cellular karyopherins [40,41].
Recently, HIV-1 CA mutant N74D was shown to escape
replication restriction observed upon TNPO3 depletion
[66]. This result reinforces previous observations for a
role of CA as the main viral determinant for TNPO3
Figure 7 IN mutants are not significantly affected at the
nuclear import step. SupT1 TL34 cells depleted for LEDGF/p75
were infected in a single round experiment with equal amounts of
WT or mutants Bru viruses. Cellular DNA was extracted and
quantified for (A) late reverse transcribed (LRT) viral cDNA products
at 7 h p.i., (B) 2-LTR circles at 24 h p.i., using a real time quantitative
PCR. (C) 2-LTR circles were normalized to LRT viral cDNA products.
Error bars represent standard deviations of n = 2 experiments
performed in duplicate. Results are expressed as the percentage of
WT products.
Cribier et al. Retrovirology 2011, 8:104
http://www.retrovirology.com/content/8/1/104
Page 9 of 14
dependency during HIV-1 infection [64-66]. However,
whereas the importance of CA as the main determinant
of TNPO3-dependency for HIV-1 replication is well
supported by experimental evidence [64-66], proof of a
direct interaction between CA and TNPO3 is still miss-
ing. Using TNPO3 as bait in a rebound yeast two-hybrid
screening against a prey library of random HIV-1 frag-
ments, we identified IN, but not CA, as the binding
partner of TNPO3 [62,63]. However, it would be impor-
tant to determine if multimerization of CA is required
for TNPO3 binding. Recently, TNPO3 has been shown
to pull-down CA as well as tRNA from purified virions
in a RanGTP-manner, and a model has been proposed
in which TNPO3 could displace CA and tRNA that
remain associated to nuclear PICs in order to facilitate
integration [78]. Whether this mechanism involves a
direct interaction between TNPO3 and CA in the
nucleus remains to be explored.
Beside the role of CA, a direct interaction between IN
and TNPO3 could take place after entry of the PIC in
the nucleus. Therefore, beside its role in nuclear import,
TNPO3 could also be involved in nuclear events of
HIV-1 replication. This model is supported by recent
findings showing that depletion of TNPO3 affected a
post-import step of HIV-1 replication [78], and it was
recently shown that by regulating nuclear import of the
PIC in a CA-dependent manner, both NUP358/RanBP2
and TNPO3 control the selection of integration sites in
the chromosomes of the host cell [79]. This latter study
proposed an interesting model in which nuclear translo-
cation through the pore would result in the specific tar-
geting of PICs in gene dense regions of the genome, a
step that could required a direct interaction between IN
and TNPO3.
An intriguing question remains regarding the pleiotro-
pic effects of the mutation W131A on HIV-1 replication.
Similar to our observations with HIV-1 W131A, a defect
of viral cDNA synthesis was also described for the VSVg-
pseudotyped HIV-1 W131A and HIV-1 W131D viruses
[15,17]. IN mutants have been reported to perturb the
reverse transcription step, possibly by altering the overall
conformation of the RTC [80]. A direct interaction
between IN and RT was reported and could account for
these effects [81]. In addition, HIV-1 viruses carrying IN
deletion or the C130S substitution were recently
described to decrease CypA-CA interaction leading to the
destabilization of the viral core [82]. Future experiments
would be required to assess the kinetic of CA uncoating
of IN mutated viruses depending of their mechanism of
entry (i.e. fusion vs. endocytosis).
Conclusion
Interactions between IN and host cellular factors control
different stages of HIV replication. TNPO3 was recently
described as a HIV-1 dependency factor able to bind
HIV-1 IN, and RNAi studies indicated that TNPO3 par-
ticipates in the import of the PIC into the nucleus
[53,55,62]. Our site-directed mutagenesis analysis aimed
at exploring the contribution of the interaction between
IN and TNPO3 to the early stages of the viral lifecycle.
The present study indicates that IN mutants W131A
and Q168L previously shown to be defective for
LEDGF/p75 were also impaired for TNPO3 binding,
albeit to a lesser extent. However, none of these muta-
tions significantly reduced the level of the 2-LTR circles,
arguing against a role of IN-TNPO3 interaction in
nuclear import.
Methods
Cells, viruses and infections
HeLa and 293T cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% of fetal calf
serum and antibiotics (100 units/ml penicillin G, 100
mg/ml streptomycin; GIBCO, Invitrogen). SupT1 and
LEDGF-depleted SupT1 TL34 cells [71] were grown in
RPMI 1640 supplemented with 10% of fetal calf serum
and antibiotics (100 units/ml penicillin G, 100 mg/ml
streptomycin; GIBCO, Invitrogen).
Viral production
Bru WT or IN mutant virus stocks were generated by
transfecting 293T cells with pBru-derived molecular
clones using PEI (Polyethylenimine, Polysciences). Cells
were washed 16 h after transfection, and supernatants
collected 24 h thereafter were filtered through 0.45 µm
filters and aliquoted. Viral stocks were quantified by
measuring the CAp24 antigen using the Innotest HIV
Antigen mAb kit, accordingly to manufacturer instruc-
tions (Innogenetics).
Viral replication
SupT1 or Sup T1 TL34 cells were infected with viral
doses corresponding to 100 ng of HIV-1 CAp24 antigen
per 2.106 cells, viral replication of each mutant viruses
compare to the WT was followed by monitoring the
HIV-1 CAp24 in the producer cells supernatants as
described above.
Plasmids and mutagenesis
His6-tagged integrases
Mutated recombinant IN Q168L, IN W131A, IN
K188Q, IN Y194E, IN Y194F were obtained by site-
directed mutagenesis of the pINSD.His plasmid [83,84].
IN mutations were introduced into the pBru molecular
clone by site-directed mutagenesis.
Expression and purification of recombinant proteins
GST-LEDGF/p75 encoding sequence was introduced in
the pGGWA plasmid using the gateway system (Invitro-
gen, Stratagene). Recombinant GST proteins were
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produced in Escherichia coli BL21. E. coli transformed
with GST-TNPO3 or GST-LEDGF/p75 expression con-
structs were grown in LB medium at 37°C to an A600 of
0.9-1.0 prior to induction with 1 mM isopropyl-thio-D-
galactopyranoside (IPTG) for 4 h at 37°C. Bacteria were
harvested by centrifugation and lysed by sonication in
GST lysis buffer A (1 M NaCl, 40 mM Hepes pH 7.0, 5
mM MgCl2, 5% glycerol, 7 mM CHAPS, 2 mM b-mer-
captoethanol) supplemented with protease inhibitor
mixture (Roche) and 1 mM phenylmethylsulfonyl fluor-
ide. Lysates were first clarified by centrifugation at
18000 × g for 50 min at 4°C and then incubated with
500 μl glutathione-Sepharose (settled beads volume, GE
Healthcare) for 1 h at 4°C. Sepharose beads were
washed twice with 20 ml of cold-ice GST lysis buffer,
and recombinant proteins were eluted in 500 μl of GST-
lysis buffer supplemented with 20 mM reduced glutha-
tione pH 7.0. His6-tagged IN WT and IN mutant pro-
teins were purified by nickel affinity as previously
described [85]. N-terminal His6-tag was removed by
digestion with 200 U/mg thrombin (Sigma) O/N at 4°C
and injected into a 5 ml HiTrap heparin column
attached to an AKTA purifier system (GE Healthcare).
Bound protein was eluted with a linear gradient of 0.25
to 1.0 M NaCl, 7 mM CHAPS, 50 mM Tris HCl pH 7.4.
His6-tag pull-down assay
Binding of IN to TNPO3, LEDGF/p75 or LEDGF/p75-
IBD was assayed in pull-down buffer (PB): 150 mM
NaCl, 25 mM Imidazole, 2 mM MgCl2, 0,1% NP40, 50
mM Tris HCl pH 7.4. Two μg of recombinant His6-
tagged HIV-1 IN were incubated with 2 μg of GST,
GST-TNPO3 FL, GST-LEDGF/p75 FL or GST-LEDGF/
p75 IBD in 200 μl of PB. Following a 2 h incubation at
4 °C, the mixtures were centrifuged briefly at full speed
to remove aggregated proteins. Samples were supple-
mented with 20 μl (settled beads volume) of Ni-charged
resin (Bio-Rad) and with 10 μg of bovine serum albumin
(BSA). The mixtures were incubated for an additional 2
h at 4°C. Beads were recovered by centrifugation and
washed three times with 1 ml of ice-cold PB. Beads
were boiled in 20 μl 2 × Laemmli (Sigma). Eluted pro-
teins were separated by SDS-PAGE and detected by
staining with Page blue protein staining solution
(Fermentas).
Size exclusion chromatography
Experiments were performed with 2.5 μM of untagged
IN on a Superdex 200 10/300 GL column attached to
an AKTA purifier system (GE Healthcare) at flow rate
0.5 ml/min in buffer containing 50 mM HEPES (pH
7.4), 750 mM NaCl, and 10% glycerol. If it was neces-
sary, proteins were diluted in this buffer before injection.
Proteins were detected by absorbance at 280 nm. The
column was calibrated with the following proteins: thyr-
oglobuline (669 kDa), apoferritine (443 kDa), b-amylase
(200 kDa), ADH (150 kDa), albumin (66 kDa) and car-
bonic anhydrase (29 kDa) (MW-GF-100 kit, Sigma).
HTRF® assay (Homogeneous Time Resolved Fluorescence)
Assays were carried out in a black 384-halfwell micro-
plate (Greiner) using the following Interaction Buffer
(IB): 25 mM Hepes pH 7.3, 150 mM NaCl, 2 mM
MgCl2, 0,1% BSA, 1 mM DTT. Recombinant proteins
were diluted in IB and used at a final concentration of
80 nM for His-IN and 5 nM for GST-TNPO3 or GST-
LEDGF/p75. Anti-GST Europium Cryptate and anti-
His-XL from CisBio International were reconstituted as
recommended. Antibodies were firstly diluted (1/200) in
IB supplemented with 0.8 mM Potassium Fluoride, 1
mM DTT and used at a final dilution 1/400. After addi-
tion of the interacting proteins and both antibodies in a
final reaction volume 20 μl, the microplate was read at
different times in a PHERAstar (BMG) at 665 and 620
nm after excitation at 337 nm. The specific HTRF signal
was expressed as a percentage of ΔF and calculated as
follows: ΔF(%)={[(665/620) sample-(665/620) blank]/
(665/620) blank}*100.
In vitro integration assays and concerted integration
3’ processing and strand transfer activity assays were
carried out at 37°C, in a buffer containing 20 mM
HEPES (pH 7.2), 1 mM DTT, 7.5 mM MnCl2 in the
presence of 12.5 nM DNA substrate and 60 nM or 120
nM of IN as previously described [86]. Products were
separated by electrophoresis in denaturing 18% acryla-
mide/urea gels. Gels were analyzed with a Molecular
Dynamics STORM phosphoimager and quantified with
Image Quant™ 4.1 software. Concerted integration was
measured as previously described [68]. Briefly purified
HIV-1 IN (2 and 5 pmoles) was pre-incubated with
both the 5’-end-labeled donor DNA (15 ng) containing
the pre-processed U3 and U5 LTR sequences and the
target DNA plasmid pBSK+ (150 ng) at 0° C for 20 min
in a total volume of 5 µl. Then the reaction mixture (20
mM HEPES, pH 7.5; 10 mM DTT; 10 mM MgCl2; 15%
DMSO; 8% PEG, 30 mM NaCl) was added and the reac-
tion proceeded for 120 min at 37°C in a total volume of
10 µL. Incubation was stopped by adding a phenol/isoa-
myl alcohol/chloroform mix (24/1/25 v/v/v). The aqu-
eous phase was loaded on a vertical 1% agarose gel in
the presence of 1% bromophenol blue and 1 mM
EDTA. After separation of the products, the gel was
treated with 5% TCA for 20 min, dried and autoradio-
graphed. All IN activities were quantified by scanning of
the bands (half-site plus full-site integration products)
after gel electrophoresis and autoradiography using the
Image J software.
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Quantification of HIV-1 late reverse transcribed (LRT) viral
cDNA products, two-LTR circles and integrated DNA
Prior to infection, viral stocks were treated 1 h at 37° C
with 100 U per ml of DNAseI (Roche). SupT1 or SupT1
TL34 cells (6.106) were infected with viral doses corre-
sponding to 1 µg of HIV-1 CAp24 antigen per 2.106
cells in 6-wells plates with Bru WT or IN mutant
viruses. At 2 h post-infection (p.i.), cells were washed
twice in phosphate buffered saline (PBS) 1X, and 2.106
cells were plated in 12 wells plates in presence of Saqui-
navir (0.5 µM) to limit viral infection to a single round.
At 7 h, 24 h and 48 h p.i. cells were harvested, washed
twice in PBS 1X and DNA was extracted using the
QIAamp Blood DNA Minikit (Qiagen). Quantifications
of viral DNA were performed by real-time PCR using
the LightCycler 480 system (Roche). The PCR reactions
contained LightCycler480 Probes Master mix including
the FastStart Taq DNA Polymerase, dNTPs and 6.4 mM
MgCl2. Primers, probes, QPCR run conditions were
described previously [87]. The copy number of HIV-1
LRT viral cDNA products and 2-LTR circles were deter-
mined using standard curves obtained by amplification
of cloned DNA containing the matched sequences. The
copy number of integrated HIV-1 DNA was determined
in reference to a standard curve generated by concomi-
tant two-stage PCR amplification of a serial dilution of
the standard HeLa R7 Neo cell DNA [88]. The copy
number of each viral form was normalized with the
number of cells obtained by the quantification by PCR
of the b-globin gene according to the manufacturer
instructions (Roche). When SupT1 TL34 cells were
used, LRT viral cDNA products were quantified using a
Taqman probe and primers within the env region as
described previously [72].
Additional material
Additional file 1: Figure S1. HIV-1 IN interacts with LEDGF/p75 and
TNPO3 in vitro. Recombinant His-IN was incubated with GST, GST-
LEDGF/p75-IBD, GST-LEDGF/p75 and GST-TNPO3 and assayed in a Ni-NTA
pull-down experiment. The pull-downed proteins were separated in SDS-
PAGE gels and detected by staining with Coomassie Blue G250. The
positions of protein MWM are indicated.
Additional file 2: Figure S2. VSVg pseudotyped HIV-1 IN mutant
viruses are affected at the reverse transcription step. HeLa cells
(2.105) were infected with viral doses corresponding to 1 μg of HIV-1
CAp24 antigen cells in 6-wells plates with VSVg pseudotyped Bru WT or
IN mutant viruses. At 7 h p.i., cells were harvested, washed twice in PBS
1X and DNA was extracted using the QIAamp Blood DNA Minikit
(Qiagen). Quantifications of LRT viral cDNA products were performed by
real-time PCR using the LightCycler 480 system (Roche).
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